

*Unless defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated 16 December 2014 (the “**Prospectus**”) issued by BBI Life Sciences Corporation (the “**Company**”).*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares being offered.

*This announcement is not an offer of securities for sale in the United States. The Company has not registered and does not intend to register any securities referred to in this announcement under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). Securities of the Company may not be offered or sold in the United States absent registration under the U.S. Securities Act or an applicable exemption from the registration requirements under the U.S. Securities Act. There will not be and is not currently intended to be any public offering of securities in the United States.*

*In connection with the Global Offering, Haitong International Securities Company Limited, as the stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriter, may effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).*

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Sunday, 18 January 2015, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, and demand for the Shares and the price of the Shares could fall.

BBI Life Sciences Corporation
BBI生命科學有限公司
(incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the : 131,166,000 Shares
Global Offering (subject to adjustment and the
Over-allotment Option)

Number of Hong Kong Public Offer : 13,119,000 Shares
Shares (subject to adjustment)

Number of International Offer : 118,047,000 Shares
Shares (subject to adjustment and the
Over-allotment Option)

Maximum Offer Price : HK\$2.21 per Offer Share (payable in
full on application, plus a brokerage
of 1.0%, an SFC transaction levy of
0.0027% and a Hong Kong Stock
Exchange trading fee of 0.005% and
subject to refund) and expected to be
not less than HK\$1.56 per Offer Share

Nominal value : HK\$0.01 per Share
Stock code : 1035

Sole Sponsor



Haitong International Capital Limited

Sole Global Coordinator, Sole Bookrunner and Sole Lead Manager



Haitong International Securities Company Limited

Application has been made by the Company to the Listing Committee for the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the Global Offering and the Capitalisation Issue (including any additional Shares which may be issued pursuant to the exercise of the Over-allotment Option and the exercise of any option which have been or may be granted under the Share Option Schemes). The Global Offering comprises (a) the Hong Kong Public Offering of 13,119,000 Shares (subject to adjustment) and (b) the International Offering of 118,047,000 Shares (subject to adjustment and the Over-allotment Option), representing approximately 10% and approximately 90%, respectively of the Shares to be issued pursuant to the Global Offering (without taking into account the exercise of the Over-allotment Option).

Subject to the granting of the approval for the listing of, and permission to deal in, the Shares on the Hong Kong Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Hong Kong Stock Exchange or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Hong Kong Stock Exchange is required to take place in CCASS on the second Business Day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS.

In connection with the International Offering, the Company is expected to grant the Over-allotment Option to the International Underwriter, exercisable by the Sole Global Coordinator at its sole and absolute discretion on behalf of the International Underwriter for up to 30 days after the last day for the lodging of applications under the Hong Kong Public Offering. Pursuant to the Over-allotment Option, the Sole Global Coordinator will have the right to require the Company to issue and allot up to an aggregate of 19,674,900 Shares, representing 15% of the initial number of the Offer Shares at the Offer Price to cover over-allocations in the International Offering, if any. The allocation of the Shares between the Hong Kong Public Offering and the International Offering is subject to adjustment as stated in the section headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation” in the Prospectus.

Assuming the Global Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Tuesday, 30 December 2014, it is expected that dealings in the Shares on the Hong Kong Stock Exchange will commence at 9:00 a.m. on Tuesday, 30 December 2014. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company on the websites of the Hong Kong Stock Exchange and the Company at www.hkexnews.hk and at <http://www.bbi-lifesciences.com>, respectively.

The Offer Price will not be more than HK\$2.21 per Offer Share and is expected to be not less than HK\$1.56 per Offer Share. Applicants for the Hong Kong Public Offer Shares are required to pay, on application, the maximum Offer Price of HK\$2.21 per Offer Share together with a brokerage of 1.0%, an SFC transaction levy of 0.0027% and a Hong Kong Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK\$2.21 per Offer Share.

Applications for the Hong Kong Public Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the Application Forms and the designated website (www.eipo.com.hk) for the White Form eIPO.

Applicants who would like to have the Hong Kong Public Offer Shares to be allotted and issued in their own names should:

- (i) complete and sign the **WHITE** Application Forms; or
- (ii) submit applications online through the designated website of the **White Form eIPO** Service Provider at www.eipo.com.hk under the **White Form eIPO** service.

Applicants who would like to have the Hong Kong Public Offer Shares to be allotted and issued in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants maintained in CCASS should either:

- (i) complete and sign the **YELLOW** Application Forms; or
- (ii) give **electronic application instructions** to HKSCC via CCASS.

Copies of the Prospectus, together with the **WHITE** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Tuesday, 16 December 2014 until 12:00 noon on Friday, 19 December 2014 from:

- (1) the following office of the Hong Kong Underwriter:

Haitong International	22/F Li Po Chun Chambers
Securities Company Limited	189 Des Voeux Road Central
	Hong Kong

(2) any of the following branches of Standard Chartered Bank (Hong Kong) Limited:

District	Branch Name	Address
Hong Kong Island	Des Voeux Road Branch	Standard Chartered Bank Building, 4-4A, Des Voeux Road Central, Central
	Wanchai Southorn Branch	Shop C2 on G/F and 1/F, Lee Wing Building, No. 156-162 Hennessy Road, Wanchai
	North Point Centre Branch	Shop G, G/F, North Point Centre, 284 King's Road, North Point
	Aberdeen Branch	Shop 4A, G/F and Shop 1, 1/F, Aberdeen Centre Site 5, No.6-12 Nam Ning Street, Aberdeen
Kowloon	Kwun Tong Hoi Yuen Road Branch	G/F, Fook Cheong Building, No. 63 Hoi Yuen Road, Kwun Tong, Kowloon.
	Tsimshatsui Branch	G/F, 8A-10 Granville Road, Tsimshatsui
	68 Nathan Road Branch	Basement, Shop B1, G/F Golden Crown Court, 66-70 Nathan Road, Tsimshatsui
New Territories	Metroplaza Branch	Shop No. 175 - 176, Level 1, Metroplaza, 223 Hing Fong Road, Kwai Chung
	Tuen Mun Town Branch	Shop No. G047 - G052, Tuen Mun Town Plaza Phase I, Tuen Mun
	Tai Po Branch	G/F shop No. 2, 23 - 25 Kwong Fuk Road, Tai Po Market, Tai Po

Copies of the Prospectus, together with the **YELLOW** Application Form, may be obtained during normal business hours from 9:00 a.m. on Tuesday, 16 December 2014 until 12:00 noon on Friday, 19 December 2014 at the **Depository Counter of HKSCC** at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or your stockbroker.

Your completed **WHITE** or **YELLOW** Application Form, together with a cheque or a banker's cashier order marked payable to "Horsford Nominees Limited — BBI Life Sciences Public Offer" attached and securely stapled, should be deposited in the special collection boxes provided at any of the branches of the receiving bank listed above, at the following dates and times:

Tuesday, 16 December 2014 — 9:00 a.m. to 5:00 p.m.

Wednesday, 17 December 2014 — 9:00 a.m. to 5:00 p.m.

Thursday, 18 December 2014 — 9:00 a.m. to 5:00 p.m.

Friday, 19 December 2014 — 9:00 a.m. to 12:00 noon

Applicants applying by **White Form eIPO** service may submit applications through the designated website at www.eipo.com.hk from 9:00 a.m. on Tuesday, 16 December 2014 until 11:30 a.m. on Friday, 19 December 2014 (24 hours daily, except on the last application day) or such later time as described in the section headed "*How to Apply for Hong Kong Public Offer Shares — Effect of Bad Weather on the Opening of the Application Lists*" in the Prospectus.

CCASS Participants can input **electronic application instructions** from 9:00 a.m. on Tuesday, 16 December 2014 until 12:00 noon on Friday, 19 December, 2014 or such later time as described in the section headed "*How to Apply for Hong Kong Public Offer Shares — Effect of Bad Weather on the Opening of the Application Lists*" in the Prospectus. Please refer to the sections headed "*Structure of the Global Offering*" and "*How to Apply for Hong Kong Public Offer Shares*" in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to publish an announcement on the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Public Offer Shares on Monday, 29 December 2014 in The Standard (in English) and the Hong Kong Economic Times (in Chinese), and on the websites of the Hong Kong Stock Exchange and the Company at www.hkexnews.hk and at <http://www.bbi-lifesciences.com>, respectively. The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be made available through a variety of channels from Monday, 29 December 2014 as described in the section headed "*How to Apply for Hong Kong Public Offer Shares — Publication of Results*" in the Prospectus.

No temporary documents of title will be issued in respect of the Shares and no receipt will be issued for sums paid on application. Share certificates will only become valid certificates of title at 8:00 a.m. on Tuesday, 30 December 2014 provided that the Global Offering has become unconditional in all respects and the right of termination described in the section headed “*Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination of the Hong Kong Underwriting Agreement*” has not been exercised.

Dealings in the Shares on the Hong Kong Stock Exchange are expected to commence at 9:00 a.m. on Tuesday, 30 December 2014. The Shares will be traded in board lots of 1,500 Shares each and the stock code of the Company is 1035.

By Order of the Board
BBI Life Sciences Corporation
Wang Qisong
Chairman

Hong Kong
16 December 2014

As at the date of this announcement, the executive Directors are Mr. Wang Qisong, Ms. Wang Luoia and Ms. Wang Jin, the non-executive Director is Mr. Hu Xubo and the independent non-executive Directors are Mr. Xia Lijun, Mr. Ho Kenneth Kai Chung and Mr. Liu Jianjun.

Please also refer to the published version of this announcement in English in The Standard and in Chinese in the Hong Kong Economic Times.